Company Profile
Inventiva Stock Price, News & Catalysts
- Ticker:
- IVA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- France and listed in the U
Stock performance
3.46 USD (-0.57%)
Close
Last updated: October 6, 2026
855M USD
Market cap
Why the stock is moving
The latest monitored company update is âInventiva prĂ©sentera plusieurs abstracts scientifiques lors de lâAASLD The Liver MeetingÂź 2026.â The corresponding closing-price reaction is not yet available.
Company overview
MASH-Focused Biopharmaceutical Company
Inventiva develops oral therapies for metabolic dysfunction-associated steatohepatitis and related liver disease. Its lead program is designed to address the metabolic, inflammatory, and fibrotic components of MASH within a single therapy.
Lanifibranor Lead Candidate
Lanifibranor is an oral pan-peroxisome proliferator-activated receptor agonist that activates PPAR alpha, delta, and gamma. This mechanism is intended to improve metabolic function while reducing inflammation and fibrosis in the liver.
Pivotal NATiV3 Program
The Phase 3 NATiV3 study is evaluating lanifibranor in adults with noncirrhotic MASH and clinically significant fibrosis. The program builds on Phase 2b data that supported advancement into registrational development.
Liver-Disease Development Infrastructure
Inventiva has concentrated its clinical, regulatory, and manufacturing resources around lanifibranor. The company also works with partners and investigators across the United States and Europe to support the global development program.
Regulatory and Commercial Preparation
The company is conducting the manufacturing, safety, and regulatory work needed to convert a positive Phase 3 result into marketing applications. Its focused structure makes lanifibranor the principal driver of both development spending and future commercial value.
Future catalysts
- Topline results from the Phase 3 NATiV3 trial of lanifibranor in the fourth quarter of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Inventiva (IVA)?
Inventiva (IVA) most recently closed at 3.46 USD, a -0.57% move versus the previous session.
What is the market cap of Inventiva (IVA)?
Inventiva currently has a market capitalization of 855M USD on BioPharmSignal.
What does Inventiva do?
MASH-Focused Biopharmaceutical Company Inventiva develops oral therapies for metabolic dysfunction-associated steatohepatitis and related liver disease. Its lead program is designed to address the metabolic, inflammatory, and fibrotic components of MASH within a single therapy. Lanifibranor Lead Candidate Lanifibranor is an oral pan-peroxisome...
On which exchange is IVA stock listed?
Inventiva (IVA) is associated with NASDAQ, France and listed in the U, Biopharma.
What is MASH-Focused?
MASH-Focused Biopharmaceutical Company Inventiva develops oral therapies for metabolic dysfunction-associated steatohepatitis and related liver disease.
Which conditions is Inventiva targeting with MASH-Focused?
Inventiva is associated with inflammatory disease, metabolic disease based on its company overview and current catalyst commentary.
How does Inventiva describe recent progress with MASH-Focused?
Topline results from the Phase 3 NATiV3 trial of lanifibranor in the fourth quarter of 2026.
What is Biopharmaceutical?
MASH-Focused Biopharmaceutical Company Inventiva develops oral therapies for metabolic dysfunction-associated steatohepatitis and related liver disease.